This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
PCSK1 · Western blot design guide
PCSK1 Western Blot Planning Guide
Plan a PCSK1 Western blot around the catalog-observed 84.2 kDa band, image-backed PA2084 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
PCSK1 Western Blot Experimental Design Guide
Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 84.2 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Adrenal gland | |
| Negative control | Bone marrow |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 84.2 kDa |
| ⓘ | Localization | Cytoplasmic vesicle, secretory vesicle |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Section 1
Real Curated PCSK1 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Adrenal gland |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PA2084 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected PCSK1 Western Blot Band Size?
Use the product-observed 84.2 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 84.2 kDa | Matches the authoritative product WB observation. |
| 84.2 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected PCSK1 appearancePlan around 84.2 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 84.2 kDa; use this as the primary experimental expectation. |
| Calculated mass | 84.2 kDa from UniProt P29120; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PA2084. |
| Situation | Likely cause | Next action |
|---|---|---|
| 84.2 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing PCSK1 band
PA2084 · PCSK1
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for PCSK1 Western blot
🧪Use Adrenal gland as the first positive-control candidate and Bone marrow as the HPA Not detected negative candidate.
Positive control: Adrenal gland (High)
Negative control: Bone marrow (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for PCSK1
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | Reported tissue cells | High | Protein (HPA) | HPA → |
| Pancreas | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Small intestine | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Cerebral cortex | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced PCSK1 Western Blot Tips
Deeper troubleshooting and optimisation questions for PCSK1, answered from its protein features.
Which band should guide the blot?
Use 84.2 kDa, the observation attached to the authoritative PA2084 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 84.2 kDa expectation.
Which positive control should I start with?
Start with Adrenal gland, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bone marrow as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for PCSK1 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PA2084 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC13174311, PMC7526459, PMC9859757.
Boster reagents
PCSK1 Western Blot Reagents
Human/Mouse/Rat-reactive PCSK1 Western blot reagents with authoritative product imagery.
Real WB data
Anti-PC1/3/PCSK1 Antibody Picoband®
Cat # PA2084
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt P29120
- Human Protein Atlas — PCSK1
- PA2084 product record
- PMC13174311 — Enteric neurons modulate colorectal cancer cell cycle through a PCSK1 - Methionine-Enkephalin Axis.
- PMC7526459 — Loss of MAGEL2 in Prader-Willi syndrome leads to decreased secretory granule and neuropeptide production.
- PMC9859757 — Sphingolipid subtypes differentially control proinsulin processing and systemic glucose homeostasis.